Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN14256 + imdevimab in COVID-19 patients without risk factors
NCT05081388Phase 2Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2021
- Primary completion
- Jun 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of REGN14256 in coronavirus disease 2019 (COVID-19), sponsored by Regeneron Pharmaceuticals. Started Nov 2021; status: terminated.
02
Drugs
REGN14256
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05081388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05081388.